Osteoarthritis (OA) affects over 595 million people worldwide, causing chronic pain and disability. With a growing aging population, cases are expected to rise significantly by 2050. Current treatments manage symptoms but cannot regenerate damaged cartilage. The need for innovative solutions has never been more urgent.

The IN-chip, a groundbreaking high-throughput 3D cartilage-on-a-chip model, is set to transform OA research and treatment. Developed by a leading consortium of experts, this device mimics the intricate microstructure and biomechanical environment of cartilage, paving the way for:

The IN-chip isn’t just a step forward—it’s a leap toward a future where OA can be cured. By enabling precise testing of potential regenerative treatments, this innovation supports healthier aging and lowers healthcare costs. Its versatility extends beyond OA, with applications in conditions like heart, lung, and eye diseases.

Through rigorous validation, standardization, and collaboration, the IN-chip consortium is committed to delivering a user-friendly, scalable product ready for commercialization. Together, we’re not only enhancing OA treatment but also reshaping the landscape of regenerative medicine and personalized healthcare.